Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.
There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

UFS student makes breakthrough in the application of nanorobots
2005-04-21

A student from the University of the Free State (UFS) has made a ground-breaking discovery in the field of microbiology by uncovering a series of new compounds that may in future be used to lubricate man-made nanorobots.

Mr Olihile Sebolai, a full-time student at the UFS’s Department of Microbial- Biochemical and Food Biotechnology, made this discovery while working on his M Sc-study on yeast.

With this discovery Mr Sebolai will also be awarded six prestigious prizes during this week’s autumn graduation ceremony at the UFS.  This university has recognised this exceptional achievement as a build-up to the celebration of national Science and Technology week next month.     

Mr Sebolai’s dissertation on the yeast genus Saccharomycopsis Schionning has been published in an accredited international journal of repute. 

“Words cannot describe how excited I am. I never expected to receive such recognition for my studies.  I am humbled by all of this,” said Mr Sebolai.

The Lipid Biotechnology Group at the UFS recently discovered that some yeasts produce their own water-propelled capsules in which they are transported.  These capsules have different shapes and resemble among others miniature flying saucers, hats with razor sharp brims etc.  “In order to function properly, parts of the capsules are oiled with prehistoric lubricants – lubricants that are produced by yeasts and that probably existed for many millions of years as yeasts developed,” said Mr Sebolai.  

According to Mr Sebolai these capsules are so small that approximately 300 can be fitted into the full-stop at the end of a sentence and are therefore invisible to the naked eye.

“With my studies I discovered many new compounds that resemble these prehistoric lubricants.  These lubricants may in future be used to lubricate man-made nanorobots and are similar in size compared to yeast capsules,” said Mr Sebolai.  The nanorobots are used to perform tasks in places that are invisible to the naked eye and could one day be used, among others, to clean up human arteries.

Mr Sebolai has been interested in the subject of Micro technology since he was at RT Mokgopa High School in Thaba ‘Nchu.  “I was specifically interested in the many possible applications the subject has – in the industry, as well as in medicine,” said Mr Sebolai. 

His next goal is to successfully complete his Ph D-degree.

The prizes that will be awarded to Mr Sebolai this week include:

Best Magister student at the UFS (Senate medal and prize);

Best Magister student in the Faculty of Natural and Agricultural Science and Dean’s medal at the same faculty;

The Andries Brink – Sasol-prize for the best M Sc dissertation in Microbiology;

The JP van der Walt prize for best M Sc dissertation in yeast science;

The Chris Small prize for an outstanding Master’s dissertation; and

Honorary colours awarded by the UFS Student Representative Council

Media release

Issued by:                     Lacea Loader

                                    Media Representative

                                    Tel:  (051) 401-2584

                                    Cell:  083 645 2454

                                    E-mail:  loaderl.stg@mail.uovs.ac.za

20 April 2005

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept